Head-to-head · free

Helus Pharma Inc. vs Kyntra Bio, Inc.

HELP vs KYNB — return on capital, cash generation, margins and balance sheet side by side.

HELP

0 / 1

measures where HELP leads

KYNB

1 / 1

measures where KYNB leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureHELPKYNB · FY2025
Revenue—$6.4M
Net income—$183.5M
Revenue growth (yearly, multi-year)—-59.3%
Free cash flow—(4.8M)
Free cash flow margin—-74.7%
Net cash / (debt)——
ROIC——
Return on equity-84.5%—
Gross margin—91.4%
Operating margin—-704.1%
Net debt / EBITDA1.10x1.06x

Figures are as reported by each company; latest fiscal year shown.

Where Helus Pharma Inc.'s cash went

Not reported yet.

Full HELP profile →

Where Kyntra Bio, Inc.'s cash went (FY2025)

Capital spending
$38000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full KYNB profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons